La Jolla's SSAO may treat multiple sclerosis, stroke, data suggests

By Elaine Rigoli

Tampa, Fla., Aug. 2 - La Jolla Pharmaceutical Co. said Wednesday that new data from animal models indicate that the company's SSAO (semicarbazide-sensitive amine oxidase) inhibitors have the potential to be used in the treatment of multiple sclerosis and stroke.

The company said its scientists have discovered several families of orally active small molecule inhibitors of SSAO that reduce disease in a variety of animal models of autoimmune disease and inflammation.

Beneficial effects have also been demonstrated in animal models of rheumatoid arthritis, ulcerative colitis and general inflammation.

La Jolla is a biotechnology company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.